With #WorldBrainTumorDay yesterday, we honor the strength & stories of children & families facing brain cancer. Gavin, a 7-yr-old living with #DIPG after receiving CAR T cell therapy in a clinical trial, inspires us as we develop BCB-276 for DIPG.
Read Gavin’s story: www.linkedin.com/pulse/car-t-...

Receiving two designations, RMAT and Breakthrough Therapy, from independent FDA reviews validates our positive #CARTcells clinical results and urgent need for a treatment for #DIPG. We're moving to initiate the pivotal trial by the end of 2025. #BrainChildTargetsCNSCancer
brainchildbio.com/press/

We’re positioned to initiate a pivotal clinical trial for an incurable brain cancer, supported by promising Ph 1 results showing an overall survival benefit in children with brain tumors treated with autologous CAR T-cell therapy.
Read more in our blog post here:
www.linkedin.com/pulse/kids-w...

Breakthrough Therapy designation gives us the possibility to accelerate the development path for BCB-276 as a CAR T-cell therapy to potentially transform treatment of #DIPG, an incurable brain tumor. Our #CARTcells approach opens a new paradigm for other CNS brain tumors.
www.brainchildbio.com/press